Multicenter, randomized, phase III trial of CD8⁺ tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinomaFIGLIN, R. A; THOMPSON, J. A; BUKOWSKI, R. M et al.Journal of clinical oncology. 1999, Vol 17, Num 8, pp 2521-2529, issn 0732-183XArticle

Gene therapy for prostate cancer : New perspectives on an old problem : Hormone refractory prostate cancerPALAPATTU, G. S; NAITOH, J; BELLDEGRUN, A. S et al.Urologic clinics of North America. 1999, Vol 26, Num 2, issn 0094-0143, ix,353-363 [12 p.]Article

Health related quality of life outcomes in patients treated for metastatic kidney cancer : A pilot studyLITWIN, M. S; FINE, J. T; DOREY, F et al.The Journal of urology. 1997, Vol 157, Num 5, pp 1608-1612, issn 0022-5347Article

Gene therapy for prostate cancer at the University of California, Los Angeles : preliminary results and future directionsPANTUCK, A. J; ZISMAN, A; BELLDEGRUN, A. S et al.World journal of urology (Print). 2000, Vol 18, Num 2, pp 143-147, issn 0724-4983Article

Superficial bladder cancer : The role of interferon-αBELLDEGRUN, A. S; FRANKLIN, J. R; O'DONNELL, M. A et al.The Journal of urology. 1998, Vol 159, Num 6, pp 1793-1801, issn 0022-5347Article

Comment se comparent néphrectomies partielles et élargies pour le traitement des carcinomes papillaires pT1aN0M0 ? Étude comparative rétrospective de 277 cas = How radical nephrectomy compares to partial nephrectomy for the treatment of pT1 a papillary renal cell carcinomas?BIGOT, P; BERNHARD, J.-C; BELLDEGRUN, A.-S et al.Progrès en urologie (Paris). 2010, Vol 20, Num 5, pp 350-355, issn 1166-7087, 6 p.Article